TY - JOUR
T1 - Targeted RMCE-live piglets generated by SCNT following sequential double site-specific gene modifications of a porcine EGFP line
AU - Perota, A
AU - Lagutina, I
AU - Duchi, R
AU - Quadalti, C
AU - Turini, P
AU - Crotti, G
AU - Colleoni, S
AU - Lazzari, G
AU - Peverali, F
AU - Lucchini, Franco
AU - Galli, C.
PY - 2014
Y1 - 2014
N2 - Site-specific nucleases (ZFN, Tal effector nucleases and
CRISPRs) boosted the genome editing of different species,
and EGFP-specific ZFNs were successfully used in rat (Geurtz
et al. 2010) and in pig (Watanabe et al. 2010, Whyte et al.
2010). Previously (Brunetti et al., 2008) we generated an EGFP
transgenic porcine line (V2G) characterized by a single
integration of pCAGGS-EGFP cassette, high ubiquitous EGFP
expression, Mendelian transgene transmission and expression
in F1. The aim of this work was to generate live cloned piglets
using modified cells after two site-specific modifications (ZFNs
and RMCE) on the transcriptionally active GFP-locus (V2G),
avoiding any cell rejuvenation by SCNT. Homology arms for
promoterless targeting vector were derived from pCAGGSEGFP
vector (promoter fragment = Left-Homology-Arm =
LHA; polyA sequence = Right-Homology-Arm = RHA).
Cloning floxed (lox2272/lox5171) puromycin and hygromycin
resistance coding sequences between LHA and RHA
sequences, and we generated the targeting/RMCE vectors
(pB50
30
Puro-PL and pB50
30
Hygro-PL) and theirs positive
controls (C+) for PCR set-up (100–1,000 plasmid copies).
V2G fibroblasts cultured in DMEM + M199(1:1) +10 %FCS,
bFGF in 5 %CO2, 5 %O2, were transfected using Nucleofector (V-024 program). In ZFN-mediated gene targeting, 2 lg of
each ZFNs coding vectors (Sigma-CompoZr ) and 2 lg of
pB50
30
Puro-PL/KpnI vector, were used to ‘nucleofect’
0.9 9 106 Verro2GFP fibroblasts. Transfected cells were
cultured under puromycin selection (2 lg/ml) for 8 days, and
0.45 9 106 cells were used for the Cre-mediated cassette
exchange (1 lg pB50
30
Hygro-PL/KpnI + 2 lg pCAG:CreEGFP).
Transfected cells were plated in 10 Petri dishes
(Ø = 150 mm) and cultured under hygromycin selection
(200 lg/ml) for 12 days, picked up and expanded in 24
multi-well plates for SCNT. Thirty-one colonies were PCR
screened for hygromycin and 16 (51.6 %) colonies were
positive for Cre-mediated targeted insertion. Four colonies
were used in zona-free SCNT experiments. On Day6, 172
compacted morulae/blastocysts were transferred into two
synchronized sows, one became pregnant and went to term
delivering seven live and four stillborn piglets. Cre-mediated
hygromycin cassette insertion into the V2G locus was PCRdetected
in all the animals that resulted also negative for
insertions of puromycin and EGFP cassettes. Combining ZFNmediated
targeting with Cre-mediated cassette exchange, we
demonstrated that two sequential site-specific modifications
could be easily done with high efficiency producing live cloned
animals. Moreover, we have validated the V2G locus as a
feasible SCNT-tested platform for further site-specific gene
modifications.
AB - Site-specific nucleases (ZFN, Tal effector nucleases and
CRISPRs) boosted the genome editing of different species,
and EGFP-specific ZFNs were successfully used in rat (Geurtz
et al. 2010) and in pig (Watanabe et al. 2010, Whyte et al.
2010). Previously (Brunetti et al., 2008) we generated an EGFP
transgenic porcine line (V2G) characterized by a single
integration of pCAGGS-EGFP cassette, high ubiquitous EGFP
expression, Mendelian transgene transmission and expression
in F1. The aim of this work was to generate live cloned piglets
using modified cells after two site-specific modifications (ZFNs
and RMCE) on the transcriptionally active GFP-locus (V2G),
avoiding any cell rejuvenation by SCNT. Homology arms for
promoterless targeting vector were derived from pCAGGSEGFP
vector (promoter fragment = Left-Homology-Arm =
LHA; polyA sequence = Right-Homology-Arm = RHA).
Cloning floxed (lox2272/lox5171) puromycin and hygromycin
resistance coding sequences between LHA and RHA
sequences, and we generated the targeting/RMCE vectors
(pB50
30
Puro-PL and pB50
30
Hygro-PL) and theirs positive
controls (C+) for PCR set-up (100–1,000 plasmid copies).
V2G fibroblasts cultured in DMEM + M199(1:1) +10 %FCS,
bFGF in 5 %CO2, 5 %O2, were transfected using Nucleofector (V-024 program). In ZFN-mediated gene targeting, 2 lg of
each ZFNs coding vectors (Sigma-CompoZr ) and 2 lg of
pB50
30
Puro-PL/KpnI vector, were used to ‘nucleofect’
0.9 9 106 Verro2GFP fibroblasts. Transfected cells were
cultured under puromycin selection (2 lg/ml) for 8 days, and
0.45 9 106 cells were used for the Cre-mediated cassette
exchange (1 lg pB50
30
Hygro-PL/KpnI + 2 lg pCAG:CreEGFP).
Transfected cells were plated in 10 Petri dishes
(Ø = 150 mm) and cultured under hygromycin selection
(200 lg/ml) for 12 days, picked up and expanded in 24
multi-well plates for SCNT. Thirty-one colonies were PCR
screened for hygromycin and 16 (51.6 %) colonies were
positive for Cre-mediated targeted insertion. Four colonies
were used in zona-free SCNT experiments. On Day6, 172
compacted morulae/blastocysts were transferred into two
synchronized sows, one became pregnant and went to term
delivering seven live and four stillborn piglets. Cre-mediated
hygromycin cassette insertion into the V2G locus was PCRdetected
in all the animals that resulted also negative for
insertions of puromycin and EGFP cassettes. Combining ZFNmediated
targeting with Cre-mediated cassette exchange, we
demonstrated that two sequential site-specific modifications
could be easily done with high efficiency producing live cloned
animals. Moreover, we have validated the V2G locus as a
feasible SCNT-tested platform for further site-specific gene
modifications.
KW - RMCE - Recombinase mediated cassette exchange
KW - Transgenic swine
KW - RMCE - Recombinase mediated cassette exchange
KW - Transgenic swine
UR - http://hdl.handle.net/10807/61942
U2 - DOI 10.1007/s11248-014-9820-1
DO - DOI 10.1007/s11248-014-9820-1
M3 - Conference article
SN - 0962-8819
VL - 23
SP - 880
EP - 881
JO - Transgenic Research
JF - Transgenic Research
T2 - Transgenic Technology Meeting (TT2014)
Y2 - 6 October 2014 through 8 October 2014
ER -